Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Iovance Biotherapeutics, Inc. - Common Stock (NQ:IOVA)

3.781 -0.079 (-2.04%)
Streaming Delayed Price Updated: 10:28 AM EST, Mar 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Iovance Biotherapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
22 23 Next >
News headline image
Gapping stocks in Thursday's session ↗
Let's have a look at the gap up and gap down stocks in today's session. 
Via Chartmill
Why Are IOVA Shares Rising Today? ↗
Via Stocktwits
News headline image
Iovance Biotherapeutics Highlights Business Achievements, Pipeline Milestones, and Third Quarter 2025 Results
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For November 6, 2025 ↗
 
Via Benzinga
News headline image
Examining the Future: Iovance Biotherapeutics's Earnings Outlook ↗
 
Via Benzinga
News headline image
Iovance Biotherapeutics Reports Potential Best-in-Class Clinical Data for Lifileucel TIL Cell Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC)
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Iovance Stock Rises 4% On Health Canada Approval For Cancer Immunotherapy: Retail Thinks ‘Patience Will Pay Off’ ↗
Via Stocktwits
Nanomedicine Innovations Transforming Oncology Drug Delivery and Bioavailability
Via Investor Brand Network
News headline image
IOVANCE INVESTIGATION REMINDER: Bragar Eagel & Squire, P.C. Continues Investigation on Behalf of Long-Term Iovance, Inc. Stockholders
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Iovance Biotherapeutics to Host Third Quarter 2025 Financial Results and Corporate Updates Webcast on Thursday, November 6, 2025
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Nanomedicine Innovations Transforming Oncology Drug Delivery and Bioavailability
EQNX::TICKER_START (OTCQB:OTLC),(NASDAQ:IOVA),(NYSE:MRK),(NYSE:LLY),(NYSE:JNJ) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Adaptimmune Plunges After Announcing Nasdaq Delisting Amidst Compliance Failures and Cost-Cutting Measures
Adaptimmune Therapeutics plc (NASDAQ: ADAP) has sent shockwaves through the biotechnology sector with its announcement on October 20, 2025, of a voluntary delisting of its American Depositary Shares... 
Via MarketMinute
Topics Initial Public Offering Regulatory Compliance Workforce
News headline image
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Turnstone Biologics: A $100 Dream Collides with a $0.34 Reality
October 17, 2025 – In the volatile world of biotechnology, ambitious price targets often fuel investor speculation and market buzz. However, for Turnstone Biologics Corp. (NASDAQ: TSTN), the notion of... 
Via MarketMinute
Topics Intellectual Property Workforce
News headline image
Better Beaten-Down Stock: Iovance Biotherapeutics vs. Teladoc Health ↗
Is there a glimmer of hope for either of these underperforming healthcare companies? 
Via The Motley Fool
News headline image
Is Iovance Biotherapeutics Stock Your Ticket to Becoming a Millionaire? ↗
Investors have certainly seen explosive gains from shares of biopharma companies in similar situations. 
Via The Motley Fool
News headline image
IOVANCE (IOVA) ALERT: Bragar Eagel & Squire, P.C. Continues Investigation into Iovance Biotherapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Can This Beaten-Down Stock Bounce Back? ↗
This biotech company is innovative, but the market demands more than that. 
Via The Motley Fool
Advancing Cancer Research Brings New Hope for Patients Worldwide
Via Investor Brand Network
Topics Artificial Intelligence Intellectual Property
News headline image
Advancing Cancer Research Brings New Hope for Patients Worldwide
EQNX::TICKER_START (OTCQB:OTLC),(NASDAQ:IOVA),(NYSE:MRK),(NASDAQ:AZN),(NYSE:BMY) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Artificial Intelligence Intellectual Property
News headline image
Iovance Biotherapeutics to Present at Upcoming Conferences
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
If You'd Invested $1,000 in IOVA 3 Years Ago, Here's How Much You'd Have Today ↗
The company hasn't been popular among investors since winning its first FDA approval more than a year ago. 
Via The Motley Fool
News headline image
Why Iovance Biotherapeutics Stock Got Mashed on Monday ↗
The company announced a flotation of its common shares that is potentially quite dilutive. 
Via The Motley Fool
News headline image
Keurig Dr Pepper, Valneva, Venu Holding And Other Big Stocks Moving Lower On Monday ↗
 
Via Benzinga
News headline image
1 Beaten-Down Stock That Could Soar By 261%, According to Wall Street ↗
Time is running out for the company to mount a comeback. 
Via The Motley Fool
News headline image
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Why Iovance Biotherapeutics Stock Was Climbing Today ↗
One and a half years after getting the nod from the U.S. Food and Drug Administration, its Amtagvi moves forward in a neighboring country. 
Via The Motley Fool
News headline image
Intel, Plymouth Industrial REIT, Premier And Other Big Stocks Moving Higher On Tuesday ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
22 23 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.